Surrozen (NASDAQ:SRZN) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Surrozen (NASDAQ:SRZN) to a strong-buy rating in a research report released on Thursday,Zacks.com reports.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $38.50.

Surrozen Stock Up 7.1%

Surrozen stock opened at $12.98 on Thursday. Surrozen has a 52 week low of $5.90 and a 52 week high of $18.17. The company’s 50 day moving average price is $12.80 and its two-hundred day moving average price is $10.59. The stock has a market cap of $111.24 million, a P/E ratio of -0.58 and a beta of 0.64.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings results on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. The business had revenue of $0.98 million for the quarter. On average, equities analysts anticipate that Surrozen will post -8.49 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC raised its stake in Surrozen by 22.6% in the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after acquiring an additional 5,702 shares during the period. Acuta Capital Partners LLC increased its stake in shares of Surrozen by 5.0% in the third quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock worth $2,299,000 after purchasing an additional 8,415 shares in the last quarter. Stonepine Capital Management LLC increased its stake in shares of Surrozen by 7.1% in the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after purchasing an additional 20,247 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its position in shares of Surrozen by 37.1% in the first quarter. Adage Capital Partners GP L.L.C. now owns 88,653 shares of the company’s stock valued at $1,034,000 after purchasing an additional 24,000 shares during the period. Finally, Nantahala Capital Management LLC lifted its stake in shares of Surrozen by 17.1% during the 1st quarter. Nantahala Capital Management LLC now owns 229,527 shares of the company’s stock valued at $2,676,000 after buying an additional 33,504 shares in the last quarter. Institutional investors own 66.57% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.